The Greek pharmaceutical company Galenica started an exceptionally important clinical study that aims at the treatment of the contemporary disease –known as functional dyspepsia.
The protocol of this research, which constitutes a landmark scientific project for the pharmaceutical company Galenica, was analyzed to all its details, during the investigators’ meeting that was held in Chalkidiki on the 17th and the 18th of September. The participants – who are clinical investigators for this study, are gastroenterology experts from 4 different countries. In particular, twenty four (24) Greek, Polish, Romanian and Turk participants, were present in this meeting in order to be able to cooperate for the completion of the clinical study that was planned and is entirely financed by the Greek pharmaceutical company Galenica.
The objective goal of this clinical study is to evaluate the efficacy and the safety of Trimebutine 300mg twice daily for the treatment of functional dyspepsia (F.D.). The duration of the clinical study is about 1 year and it will be preformed in 12 centres in Greece, Turkey, Romania and Poland. The total patients who will participate in the study will be 240.
It is worth mentioning that the pharmaceutical company Galenica is the first Greek company that plans, finances and monitors a phase III multinational clinical study.
Ελληνικά